Versant Ventures will file an early warning report regarding Repare Therapeutics Inc.

VANCOUVER, British Columbia and MONTREAL–(BUSINESS WIRE)–Versant Companies today announced that it will be filing an alert report regarding the ownership of securities of Repare Therapeutics Inc. (the “Company”) by Versant Venture Capital VI, LP, Versant Vantage I, LP, Versant Venture Capital V, LP , Versant Venture Capital V (Canada) LP, Versant Ophthalmic Affiliates Fund I, LP and Versant Affiliates Fund V, LP (collectively, the “Versant Funds”).

On May 5, 2021, June 1, 2021 and August 5, 2021, certain of the Versant Funds distributed an aggregate of 467,817 common shares of the Company (the “Common Shares”) pursuant to discretionary distributions and distributions under the Versant Funds’ automatic securities disposition plans (the “PDAS”) and on June 3 2022, certain of the Versant Funds sold a total of 750,000 common shares for gross proceeds of $9,188,775, or an average price of $12.2517 per common share. The 467,817 common shares distributed under the PDSAs are referred to as the “Distributed Shares” and the 750,000 common shares sold on June 3, 2022 are referred to as the “Tendered Shares”.

The Versant Funds previously adopted the PDSAs to facilitate the distribution of common stock to associates of the Versant Funds in the amounts and based on the closing price triggers specified in the PDSAs, and without additional consideration.

Prior to the disposition of the Distributed Shares and Distributed Shares, the Versant Funds beneficially owned and controlled or directed 5,462,679 common shares of the Company, representing approximately 13.04% of the common shares outstanding as of June 3. 2022. The total of 1,217,817 shares distributed and shares disposed of represent approximately 2.91% of the common shares outstanding.

Immediately following the disposition of the Distributed Shares and the Tendered Shares, the Versant Funds beneficially owns and controls or directs 4,244,862 common shares of the Company, representing approximately 10.13% of the common shares outstanding.

The distributed shares were distributed to partners of the Versant Funds without additional consideration. The distributed shares were sold pursuant to normal course transactions conducted through a broker using specific pricing instructions through customary Rule 10b5-1 programs furthering the investment objectives of the Versant Funds , and in the future, the Versant Funds may discuss with management and/or the Board of Directors of the Company business transactions and other opportunities and may additionally buy, hold, vote, exchange, assign or otherwise deal securities of the Company, in such manner as they deem desirable, depending on market and other conditions.

The Versant Funds reserve the right, depending on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional Common Shares or other securities of the Company, to dispose of any or all of the common stock Shares or other securities of the Company which it may hold from time to time, in each case in connection with open market or private transactions, sales in block or otherwise or in connection with ordinary exchange transactions effected through one or more brokers, either individually or using pricing or other instructions (including through customary Rule 10b5-1 programs ), and review or reconsider their position, change their purpose, take other action, or formulate and implement plans or proposals regarding any of the foregoing.

The Versant Funds intend to review their investment in the Company from time to time based on a variety of factors, including the Company’s business, financial condition, results of operations and prospects, general economic and industry conditions. , the securities markets in general and those of the Company’s shares in particular, as well as other developments.

An alert statement will be filed by the Versant Funds in accordance with applicable securities laws and will be available on SEDAR under the Company’s profile at www.sedar.com or can be obtained directly from Versant Funds upon request at the telephone number below. The head office of the Company is located at 7210 Frederick-Banting, Suite 100, Montreal, Quebec H4S 2A1. The address of each of the Versant Funds is One Sansome Street, Suite 3630, San Francisco, CA 94104. Each of the Versant Funds is organized under the laws of Delaware. with the exception of Versant Venture Capital V (Canada) LP which is incorporated under the laws of Ontario, Canada. The primary business of the Versant Funds is to invest in biotechnology companies.

contacts

Steve Edelson, Vice President, Investor Relations and Communications

415-801-8088

[email protected]